Diamond Equity Estimates MAIA Biotechnology Q1 Earnings

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) – Diamond Equity issued their Q1 2025 earnings per share (EPS) estimates for MAIA Biotechnology in a research note issued to investors on Thursday, November 14th. Diamond Equity analyst H. Diamond forecasts that the company will post earnings of ($0.25) per share for the quarter. The consensus estimate for MAIA Biotechnology’s current full-year earnings is ($1.25) per share. Diamond Equity also issued estimates for MAIA Biotechnology’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.43) EPS and FY2025 earnings at ($1.35) EPS.

MAIA Biotechnology Stock Performance

MAIA Biotechnology stock opened at $2.19 on Monday. The firm has a market capitalization of $55.47 million, a price-to-earnings ratio of -1.59 and a beta of 0.32. MAIA Biotechnology has a 1-year low of $0.82 and a 1-year high of $5.99.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.21.

Hedge Funds Weigh In On MAIA Biotechnology

Several institutional investors have recently added to or reduced their stakes in MAIA. Geode Capital Management LLC grew its holdings in MAIA Biotechnology by 22.9% during the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after purchasing an additional 35,821 shares during the period. Virtu Financial LLC bought a new position in shares of MAIA Biotechnology during the 1st quarter worth $71,000. Ground Swell Capital LLC purchased a new stake in MAIA Biotechnology in the 2nd quarter worth about $56,000. Mather Group LLC. raised its stake in MAIA Biotechnology by 50,150.0% in the 2nd quarter. Mather Group LLC. now owns 12,060 shares of the company’s stock valued at $41,000 after acquiring an additional 12,036 shares during the period. Finally, XTX Topco Ltd purchased a new stake in MAIA Biotechnology during the third quarter valued at about $31,000. Institutional investors own 5.65% of the company’s stock.

Insider Activity at MAIA Biotechnology

In other news, Director Cristian Luput bought 22,133 shares of the company’s stock in a transaction on Friday, November 1st. The shares were purchased at an average price of $2.51 per share, with a total value of $55,553.83. Following the transaction, the director now directly owns 389,483 shares in the company, valued at $977,602.33. This represents a 6.03 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 36.98% of the stock is currently owned by insiders.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.